Research: LOU and COLLEAGUES,

Listed in Issue 246

Abstract

LOU and COLLEAGUES, (1)Department of Hematology, Institute of Hematology, The First Affiliated Hospital  of Zhejiang University, School of Medicine, PR China analyzed additional chromosome abnormalities (ACAs) in  newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide (ATO) as the front-line therapy.

Background

Currently, there are few studies that address the prognostic significance of baseline additional chromosomal abnormalities (ACAs) in newly diagnosed acute promyelocytic leukemia (APL) patients treated with arsenic trioxide (ATO) as the front-line therapy.

Methodology

A series of 271 consecutive APL patients has been cytogenetically investigated between 2004 and 2011 in our institution. The incidence of ACAs was 27% (46/172) in APL cases with t(15;17). Trisomy 8 was the most recurrent abnormality, accounting for 30% (14/46) of patients with ACAs, followed by +21 (7%, 3/46) and -7/7q (7%, 3/46). Nine cases (14.1%) were found to have additional balanced translocation aberrations, most of them are new and non-recurrent. Treatment protocols consisted of all-trans retinoic acid (ATRA) and chemotherapy with or without the ATO therapy.

Results

Overall, patients with and without ACAs had similar complete remission (CR) rates (94% and 98%, respectively, P=0.344). With a median follow-up of 41 months, univariate analysis showed that ACAs did not show any prognostic significance in relapse-free survival (RFS) and overall survival (OS). In addition, ATO treatment was an independent favourable predictor for RFS.

Conclusion

Thus, this data provides insights into cytogenetic features of APL, and suggests that ATO-based combination therapy improved RFS in de novo APL patients, while ACAs had no impact on prognosis.

References

Lou Y(1), Suo S, Tong H, Ye X, Wang Y, Chen Z, Qian W, Meng H, Mai W, Huang J, Tong Y, Jin J. Characteristics and prognosis analysis of additional chromosome abnormalities in  newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.  Leuk Res. 37(11):1451-6. Nov 2013. doi: 10.1016/j.leukres.2013.07.030. Epub Aug 16 2013. Comment in   Leuk Res. 37(11):1434-5. Nov 2013.

Munro Hall Clinic 2019

IJCA 2018 New Skyscraper

Scientific and Medical Network 2

Cycle India 2020

Walk on the Wide Side Trek Kenya 2020

Big Heart Bike Ride South Africa 2020

top of the page